London, UK
The leading dedicated end-to-end summit focused on the global delivery of safe, effective and commercially successful CAR and TCR cell immunotherapies.
With the first two CAR-T’s approved, both pending approval in the EU and Kymriah expanding approval in more indications, CAR-T therapies aren’t going anywhere and are set to become mainstream frontline cancer treatments. BUT as we see success, there are still two key areas for even the leaders to address: European regulations and global distribution. Alongside this, the challenges with improving the underwhelming performance of CAR-TCR therapies in solid tumor indications are more important now than ever before. With the only promising solid tumor data in TCR approaches, what will the successful future of CAR-T and TCR therapies look like?
The CAR-TCR Summit Europe brings you access to the leaders in this field and the hub of companies creating novel innovations in Europe. We set the stage for visionary leaders to transform the commercial and clinical delivery of cancer therapeutics. Gain exclusive insight on current clinical programs and case studies on the wave of next generation CAR-TCR candidates from those pioneering in this field.
Focusing on navigating the regulatory minefield, ensuring successful global distribution and successful delivery of CAR-T and TCR therapies, CAR-TCR Summit Europe is your opportunity to network, interact and learn at the only end-to-end meeting that fosters the transformation of leading science to commercial therapies.
Wednesday, 21st, 2018
12.30 RNAscope™ Platform: Enabling Preclinical and Clinical T Cell Therapy PK/PD Analysis, Target Engagement and Biomarker Analysis
Christopher BunkerVice President, Business Development, ACD
Synopsis
- The most sensitive and specific method for tissue-based target safety assessment
- A universal method for virally-transduced T cell biodistribution analysis
- Simple multiplexed analysis of CAR/TCR-T cells, TILs, CTL activity and targets
- Integrated biomarker development, clinical validation and CDx
